AB004. New technology and therapy for bladder cancer
Plenary Session

AB004. New technology and therapy for bladder cancer

Max Meng

Department of Urology, University of California, San Francisco, CA, USA


Abstract: Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundamentally changed over the past decade. In this lecture, we will discuss (I) new technology in the detection and monitoring of non-invasive disease (blue-light and narrow band imaging); (II) the role of lymphadenectomy at the time of cystectomy; (III) a novel risk stratification tool predicting prognosis after cystectomy; and (IV) systemic therapies and clinical trials for advanced and refractory disease.

Keywords: New technology; therapy; bladder cancer


doi: 10.21037/tau.2016.s004


Cite this abstract as: Meng M. New technology and therapy for bladder cancer. Transl Androl Urol 2016;5(Suppl 1):AB004. doi: 10.21037/tau.2016.s004

Article Options

Download Citation